|

Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis

RECRUITINGSponsored by Military Medical Clinical Center of the Southern Region, Ukraine
Actively Recruiting
SponsorMilitary Medical Clinical Center of the Southern Region, Ukraine
Started2026-05-01
Est. completion2026-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07536841

Summary

This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
* Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
* Ability to provide informed consent (for prospective participants).

Exclusion Criteria:

* Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
* Incomplete diagnostic data preventing OC26 scoring.
* Prior pancreatic surgery altering diagnostic interpretation.

Conditions5

Autoimmune PancreatitisCancerChronic PancreatitisIgG4-Related DiseasesPancreatic Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.